Eosinophil activation markers in clonal and non-clonal eosinophilia

1. Rosenberg H.F.,Dyer K.D.,Foster P.S. Eosinophils: changing perspectives in health and Disease. Nat Rev Immunol. 2013 Jan;13(1):9-22.10.1038/nri3341435749223154224Search in Google Scholar

2. Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy. 2008 May;38(5):709-50.10.1111/j.1365-2222.2008.02958.x18384431Search in Google Scholar

3. Jacobsen EA,Richard A. Helmers2, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood. 2012 Nov 8;120(19):3882-90.10.1182/blood-2012-06-330845349695022936660Search in Google Scholar

4. Horny HP, Sotlar K, Valent P. Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis. Journal of Hematopathology. 2011;4(2):101-111.10.1007/s12308-011-0094-8Search in Google Scholar

5. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol. 2006 Jun;133(5):468-92.10.1111/j.1365-2141.2006.06038.x16681635Search in Google Scholar

6. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30;114(5):937-51.10.1182/blood-2009-03-20926219357394Search in Google Scholar

7. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophilic disorders. Blood Rev. 2009 Jul;23(4):157-65.10.1016/j.blre.2009.01.00119246139Search in Google Scholar

8. Chusid MJ, Dale CD, West BC, Wolff SM .The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975 Jan;54(1):1-27.10.1097/00005792-197501000-00001Search in Google Scholar

9. Park YJ, Oh EJ, Park JW, Kim M, Han K. Plasma eosinophil cationic protein, interleukin-5, and ECP/Eo count ratio in patients with various eosinophilic diseases. Ann Clin Lab Sci. 2006;36(3):262-6.Search in Google Scholar

10. Venge P, Bystrom J, Carlson M, Hakansson L, Karawacjzyk M, Peterson C, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy. 1999 Sep;29(9):1172-86.10.1046/j.1365-2222.1999.00542.x10469025Search in Google Scholar

11. Davies L, Gather U. The Identification of Multiple Outliers. Journal of the American Statistical Association. 1993 Sep;88(423):782-92.10.1080/01621459.1993.10476339Search in Google Scholar

12. Rousseeuw PJ, Croux C. Alternatives to the Median Absolute Deviation. Journal of the American Statistical Association. 1993 Sep;88(424):173-83.10.1080/01621459.1993.10476408Search in Google Scholar

13. Mizera I, Muller CH. Location-Scale Depth. Journal of the American Statistical Association. 2004 Dec;99(468):949-89.10.1198/016214504000001312Search in Google Scholar

14. Gotlib J. Eosinophilic myeloid disorders: new classification and novel therapeutic strategies. Curr Opin Hematol. 2010 Mar;17(2):117-24.10.1097/MOH.0b013e3283366c7020071982Search in Google Scholar

15. Liso V., Troccoli G., Specchia G. and Magno M. Cytochemical “normal” and “abnormal” eosinophils in acute leukemias. Am J Hematol. 1977;2(2): 123-31.10.1002/ajh.283002020470168Search in Google Scholar

16. Karasuyama H, Mukai K, Tsujimura Y, Obata K. Newly discovered roles for basophils: a neglected minority gains new respect. Nat Rev Immunol. 2009 Jan;9(1): 9-13.10.1038/nri245819039320Search in Google Scholar

17. Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood. 1999 Mar 1;93(5):1651-7.10.1182/blood.V93.5.1651.405k20_1651_1657Search in Google Scholar

18. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003 Mar 27;348(13):1201-14.10.1056/NEJMoa02521712660384Search in Google Scholar

19. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007 Aug 10;25(23): 3503-10.10.1200/JCO.2006.08.569617687155Search in Google Scholar

20. Matsushima T, Handa H, Yokohama A, Nagasaki J, Koiso H, Kin K, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood. 2003 May 1;101(9):3386-90.10.1182/blood-2002-03-094712506028Search in Google Scholar

21. Roufosse F, Garaud S, de Leval L. Lymphoproliferative Disorders Associated With Hypereosinophilia. Semin Hematol. 2012 Apr;49(2):138-48.10.1053/j.seminhematol.2012.01.00322449624Search in Google Scholar

22. von Wasielewski R, Seth S, Franklin J, Fischer R, Hubner K, Hansmann ML et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. 2000 Feb 15;95(4):1207-13.10.1182/blood.V95.4.1207.004k34_1207_1213Search in Google Scholar

23. Stanelle J, Doring C, Hansmann ML, Kuppers R. Mechanisms of aberrant GATA3 expression in classical Hodgkin lymphoma and its consequences for the cytokine profile of Hodgkin and Reed/Sternberg cells. Blood. 2010 Nov 18;116(20):4202-11.10.1182/blood-2010-01-26582720660789Search in Google Scholar

24. Chu VT, Frohlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat Immunol. 2011 Feb; 12(2):151-9.10.1038/ni.198121217761Search in Google Scholar

25. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007 Apr 1;178(7):4222-9.10.4049/jimmunol.178.7.422217371978Search in Google Scholar

26. Cormier S, Taranova A, Bedient C, Nguyen T, Protheroe C, Pero R et al. Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol. 2006 Jun; 79(6):1131-9. 10.1189/jlb.0106027349642216617160Search in Google Scholar